Market Research Future (MRFR) has announced the release of a new market research report on the global transplant diagnostics market. The report examines the possible global growth trajectory of the transplant diagnostics market based on a detailed study of the historical growth patterns of the market and the market’s key growth drivers and restraints. According to the report, the Global Transplant Diagnostics Market is expected to reach a valuation of USD 2,074.65 million by 2023 at a strong CAGR of 7.80% over the forecast period from 2018 to 2023.
Transplant Diagnostics is a medical field concerned with diagnosing the compatibility of human tissues and organs that are being transplanted. The global transplant diagnostics market has grown at a steady growth rate over the last few years due to the growing demand for organ transplants. The rising prevalence of chronic diseases has been a key factor in the growing demand for organ transplants, as chronic diseases such as diabetes often lead to the loss of organs, as it has an adverse effect on all organ systems, which may be particularly prominent in the case of some organs.
Transplant Diagnostics plays a vital role in reducing the chances of organ rejection. Organ rejection can have catastrophic consequences for the recipient, as the body treats it as a foreign object and takes defensive actions accordingly. This can develop into a bigger issue than the medical condition being treated by replacing the organ in the first place. This has made transplant diagnostics highly important in the healthcare sector and is likely to enable consistent growth of the global market for the same over the forecast period.
Global Transplant Diagnostics Market – Key Players
Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Becton Dickinson and Company (US), Abbott Laboratories Inc (US), CareDx (US), Qiagen N.V. (Netherlands), Immucor, Inc. (US), GenDx (Netherlands), Omixon Ltd. (UK), bioMérieux S.A. (France), Illumina, Inc. (US), Immucor Transplant Diagnostics, Inc (US), Affymetrix, Inc (US), Linkage Biosciences (US)
Get Free Sample Report @ https://www.marketresearchfuture.com/sample_request/1324
Global Transplant Diagnostics Market – Segmentation
The Global Transplant Diagnostics Market has been segmented based on product and services, screening type, organ type, application type and end-users. Based on product and services, the transplant diagnostics market is segmented into instruments, reagents and consumables, software and services. Based on screening type, the transplant diagnostics market is segmented into pre-transplant screening and post-transplant screening.
Based on organ type, the Transplant Diagnostics Market is segmented into kidney, pancreas, liver, heart, lungs and others. Based on application type, the transplant diagnostics market is segmented into research applications, diagnostic applications and others. Based on end-users, the transplant diagnostics market is segmented into commercial service providers, hospital and transplant centers, research laboratories and academic institutes, and others.
Industry Updates:
In December 2018, Novacyt launched two new diagnostic test kits for post-transplant monitoring. These include the genesig Real-Time PCR BK virus (BKV) Kit (CE) and genesig Real-Time PCR Epstein-Barr Virus (EBV) Kit (CE).
December 2018, CareDx Inc. released new data confirming the utility of its AlloSure test to diagnose allograft health in repeat kidney transplant patients.
In May 2018, CareDx, a U.S.-based molecular diagnostics company, has announced the signing of licensing and commercialization agreement with Illumina, a provider of next-generation sequencing solutions. CareDx is now the exclusive worldwide distributor of Illumina’s TruSight HLA v1 and v2 product lines which will be used for bone marrow transplantation diagnostic testing and solid organ transplantation diagnostic testing.
TAI Diagnostics which is US based company and develops non-invasive test to monitor patients’ health after they’ve got heart transplants, has scheduled to initiate selling their test early next year. They have generated about $13 million from their investors so far. The company is presently raising more money to supplement its $8.3 million Series A funding round. The extension could bring TAI’s total outside financing to $21 million, the startup’s test measures levels of cell-free DNA, genetic material released by the transplant recipient’s new heart that can enter the bloodstream, to assess whether they are in danger of rejecting the organ.
Thermo Fisher Scientific Acquires Linkage Bio: on July 2017 Thermo Fisher Scientific confirmed the company’s acquisition of Linkage Biosciences for an undisclosed amount, as a result of this acquisition Linkage Biosciences is now a part of Thermo Fisher’s transplant diagnostics business. The company based in South San Francisco, California. Benefits involved from the acquisition include a broader and deeper range of products, a continued commitment to innovation, and expanded support globally.
The business is extremely complementary to the company’s One Lambda tests, which regulate the compatibility of donors and recipients pre- and post-transplant. This acquisition further expands Thermo Fisher’s commitment of improving transplant patients’ quality of life over innovative high-quality products for the clinical and research segments of the transplant community.
Global Transplant Diagnostics Market – Regional Analysis
Geographically, the Global Transplant Diagnostics Market is segmented into four major regions such as Americas, Europe, Asia Pacific and the Middle East and Africa. Among these regions, the Americas are dominating the global transplant diagnostics market owing to the increasing prevalence of chronic diseases leading to organ failure and rapid technological development aiding in the automation of the diagnostic procedures in the healthcare sector of this region.
The Europe region accounts for the second largest share in the global transplant diagnostics market. The transplant diagnostics market in this region is driven by the easy adoption of advanced healthcare technologies, active involvement of the government for spreading awareness, and availability of donated organs due to the initiatives that were taken by the European Commission for organ harvesting.
The Asia Pacific region is anticipated to project significant growth in the global transplant diagnostics market due to the rapid increase in geriatric population and increasing incidences of organ failure in this region. The high investment in stem cell technology for organ development and in-vitro tissue are some of the crucial factors that are driving the transplant diagnostics market in this region.
The lack of awareness, less technological penetration and poor healthcare infrastructure in the underdeveloped areas of the Middle East and Africa region are hampering the growth of the global transplant diagnostics market.
Browse Complete 100 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/transplant-diagnostics-market-1324
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/transplant-diagnostics-market-1324